^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:carmustine (DNA synthesis inhibitor, Alkylating agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/16/2022
    Excerpt:
    Carmustine for Injection is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following...Multiple myeloma-in combination with prednisone…
    Secondary therapy:
    Chemotherapy + prednisone